Mylan (MYL) Given a $41.00 Price Target at Cantor Fitzgerald

Cantor Fitzgerald set a $41.00 price target on Mylan (NASDAQ:MYL) in a report published on Tuesday. The brokerage currently has a hold rating on the stock.

Other equities research analysts also recently issued research reports about the stock. Citigroup set a $42.00 target price on shares of Mylan and gave the stock a buy rating in a research report on Wednesday, October 4th. Zacks Investment Research raised shares of Mylan from a strong sell rating to a hold rating and set a $43.00 target price for the company in a research report on Tuesday, October 10th. BidaskClub raised shares of Mylan from a strong sell rating to a sell rating in a research report on Thursday, September 7th. Guggenheim began coverage on shares of Mylan in a research report on Tuesday, December 12th. They issued a buy rating and a $59.00 target price for the company. Finally, Instinet reaffirmed a buy rating and issued a $37.00 target price on shares of Mylan in a research report on Thursday, October 5th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Mylan currently has an average rating of Buy and a consensus target price of $42.78.

Shares of Mylan (NASDAQ:MYL) opened at $42.27 on Tuesday. The firm has a market cap of $22,557.14, a P/E ratio of 26.25, a P/E/G ratio of 3.13 and a beta of 1.38. The company has a current ratio of 1.46, a quick ratio of 0.95 and a debt-to-equity ratio of 1.05. Mylan has a 1 year low of $29.39 and a 1 year high of $45.87.

Mylan (NASDAQ:MYL) last announced its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion for the quarter, compared to the consensus estimate of $3.09 billion. Mylan had a net margin of 7.28% and a return on equity of 20.63%. Mylan’s revenue was down 2.3% on a year-over-year basis. During the same period last year, the business earned $1.38 EPS. research analysts forecast that Mylan will post 4.56 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of the company. Greenlight Capital Inc. grew its position in shares of Mylan by 0.4% during the 3rd quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock valued at $337,048,000 after acquiring an additional 42,600 shares during the period. Wealthsource Partners LLC grew its position in shares of Mylan by 57.6% during the 3rd quarter. Wealthsource Partners LLC now owns 14,705 shares of the company’s stock valued at $461,000 after acquiring an additional 5,375 shares during the period. Americafirst Capital Management LLC bought a new stake in shares of Mylan during the 3rd quarter valued at $471,000. Cypress Capital Group grew its position in shares of Mylan by 37.7% during the 3rd quarter. Cypress Capital Group now owns 13,079 shares of the company’s stock valued at $410,000 after acquiring an additional 3,579 shares during the period. Finally, California Public Employees Retirement System grew its position in shares of Mylan by 4.2% during the 3rd quarter. California Public Employees Retirement System now owns 1,129,978 shares of the company’s stock valued at $35,447,000 after acquiring an additional 45,822 shares during the period. 74.90% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Week Herald and is the property of of Week Herald. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://weekherald.com/2017/12/27/mylan-myl-given-a-41-00-price-target-at-cantor-fitzgerald-2.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan (NASDAQ:MYL)

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply